Trademark Search in Canada

REGKIRONA

View On IC.GC.CA

REGISTERED

on 1 Dec 2023

Last Applicant/ Owned by

CELLTRION INC.

23, Academy-ro,Yeonsu-guIncheon

Serial Number

2118343 filed on 21^st May 2021

Registration Number

TMA1211918 registered on 1^st Dec 2023

Registration expiry Date

21^st May 2031

Correspondent Address

SMART & BIGGAR LP

SCOTIA PLAZA40 KING STREET WEST40th FLOORTORONTO

ONTARIO

M5H3Y2

REGKIRONA

Trademark usage description

pharmaceutical preparations for the treatment of covid-19; pharmaceutical antibodies for the treatment of covid-19; pharmaceuticals for the treatment Read More

Classification Information

Class [005]
Pharmaceutical preparations for the treatment of COVID-19; pharmaceutical antibodies for the treatment of COVID-19; pharmaceuticals for the treatment of COVID-19; drugs for medical purposes for the treatment of COVID-19.

Classification kind code

Mark Details

Serial Number

2118343

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 48 on 20^th Oct 2022	Agent Changed
Submitted for opposition 22 on 11^th Oct 2022	Search Recorded
Submitted for opposition 20 on 11^th Oct 2022	Examiner's First Report
Submitted for opposition 223 on 11^th Oct 2022	Total Provisional Refusal
Submitted for opposition 256 on 2^th May 2022	Notification of Possible Opposition Sent
Submitted for opposition 257 on 1^st Jul 2021	Designation Notification - Madrid Protocol
Submitted for opposition 1 on 1^st Jul 2021	Created
Submitted for opposition 31 on 1^st Jul 2021	Formalized
Submitted for opposition 228 on 21^st May 2021	International Registration
Submitted for opposition 30 on 21^st May 2021	Filed

REGKIRONA

Classification Information

Class [005]Pharmaceutical preparations for the treatment of COVID-19; pharmaceutical antibodies for the treatment of COVID-19; pharmaceuticals for the treatment of COVID-19; drugs for medical purposes for the treatment of COVID-19.

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [005]
Pharmaceutical preparations for the treatment of COVID-19; pharmaceutical antibodies for the treatment of COVID-19; pharmaceuticals for the treatment of COVID-19; drugs for medical purposes for the treatment of COVID-19.